Directive 75/318/EEC is a European Community legal instrument adopted on 20 June 1975. Its full title is “Directive of the Council of 20 June 1975 concerning the mutual recognition of the marketing authorisation of medicinal products for human use and the procedures for the co‑ordination of the assessment of applications for marketing authorisation.” The directive established a framework for the mutual recognition of national marketing authorisations for pharmaceuticals among Member States of the European Economic Community (EEC). Its primary objectives were to:
- Facilitate the free movement of medicinal products within the Community by allowing a product authorised in one Member State to be marketed in others, subject to mutual recognition procedures.
- Create a coordinated system for the assessment of marketing authorisation applications, including the establishment of a “centralised” procedure for certain categories of drugs.
- Ensure a consistent standard of safety, efficacy, and quality for medicinal products across the Community.
Key provisions of the directive included:
- Mutual Recognition Procedure – A Member State that had granted a marketing authorisation could request other Member States to recognise that authorisation, provided the product complied with the Community’s basic requirements.
- Co‑ordination Procedure – For products not covered by the mutual recognition route, a co‑ordination mechanism allowed Member States to jointly assess the application, aiming to avoid duplicative assessments.
- Scope – The directive applied to both prescription and non‑prescription medicines intended for human use. It did not cover veterinary medicinal products, which were later addressed by a separate directive.
Amendments and subsequent developments:
- Directive 75/319/EEC (1975) introduced provisions for the mutual recognition of veterinary medicinal products.
- Over time, the framework established by Directive 75/318/EEC was superseded by more comprehensive legislation, notably Directive 2001/83/EC (Human Medicines) and Directive 2001/82/EC (Veterinary Medicines), which incorporated the principles of mutual recognition into a modernised regulatory system.
- The original directive was formally repealed by the later directives, which continue to govern the marketing authorisation and mutual recognition processes within the European Union.
Historical significance:
Directive 75/318/EEC was a foundational element in the development of a single European pharmaceutical market. By standardising the procedures for market authorisation and promoting mutual recognition, it contributed to the reduction of regulatory barriers, facilitated cross‑border trade of medicines, and laid the groundwork for the EU’s current centralised authorisation system managed by the European Medicines Agency (EMA).
